Patient baseline characteristics and efficacy summary*
| Characteristic | All patients | Sofosbuvir+ ledipasvir | Glecaprevir+ pibrentasvir | Sofosbuvir+ velpatasvir | P value |
| Total case number | 470 (100) | 50 (10.64) | 345 (73.40) | 75 (15.96) | |
| Male | 329 (70.00) | 34 (68.00) | 243 (70.43) | 52 (69.33) | 0.931 |
| Age | 44 (27–69) | 44 (27–62) | 44 (28–69) | 44 (34–69) | 0.997 |
| HCV genotype: 1 | 208 (44.26) | 29 (58.00) | 146 (42.32) | 33 (44.00) | 0.113 |
| HCV genotype: 2 | 60 (12.77) | 7 (14.00) | 40 (11.59) | 13 (17.33) | 0.387 |
| HCV genotype: 3 | 75 (15.96) | 0 (0.00) | 65 (18.84) | 10 (13.33) | 0.002 |
| HCV genotype: 6 | 125 (26.60) | 14 (28.00) | 92 (26.67) | 19 (25.33) | 0.945 |
| HBV coinfection | 44 (9.36) | 3 (6.00) | 34 (9.86) | 7 (9.33) | 0.682 |
| HIV coinfection | 71 (15.11) | 12 (24.00) | 50 (14.49) | 9 (12.00) | 0.153 |
| PWID | 240 (51.06) | 31 (62.00) | 175 (50.72) | 34 (45.33) | 0.274 |
| Liver cirrhosis | 51 (10.85) | 22 (44.00) | 23 (6.67) | 6 (8.00) | 0.001 |
| Child-Turcotte-Pugh score A | 49 (10.43) | 21 (42.00) | 23 (6.67) | 5 (6.67) | |
| Child-Turcotte-Pugh score B | 2 (0.43) | 1 (2.00) | 0 (0.00) | 1 (1.33) | |
| Child-Turcotte-Pugh score C | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| History of decompensated liver disease | 7 (1.49) | 1 (2.00) | 3 (0.87) | 3 (4.00) | 0.122 |
| History of HCC | 1 (0.21) | 0 (0.00) | 1 (0.29) | 0 (0.00) | 0.375 |
| Interferon-experienced treatment | 13 (2.77) | 3 (6.00) | 7 (2.03) | 3 (4.00) | 0.216 |
| CKD stage 3 or haemodialysis | 9 (1.91) | 0 (0.00) | 8 (2.32) | 1 (1.33) | 0.834 |
*Data are presented as number (%) or median (range).
CKD, chronic kidney disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PWID, people who inject drugs.